Detalhe da pesquisa
1.
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.
Gynecol Oncol
; 127(1): 55-62, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22664059
2.
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Lancet Oncol
; 11(10): 962-72, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20851682
3.
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Thyroid
; 30(9): 1254-1262, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32538690
4.
Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
Endocrine
; 57(2): 220-225, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28685225
5.
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
J Clin Endocrinol Metab
; 99(5): 1687-93, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24606083
6.
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.
J Clin Endocrinol Metab
; 97(9): 3179-84, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22774206
7.
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
J Clin Oncol
; 28(19): e312-3, 2010 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20516434